Evidence map›Paper›PMID 40793976›Full record

ArticleJournal of comparative effectiveness research2025

Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma.

Jianming He, Karen Chiang, Xiwu Lin, Winghan Jacqueline Kwong, John Maringwa, Lingfeng Yang, Sandhya Nair, Mahmoud Hashim, Mi Jun Keng, Imtiaz A Samjoo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jianming HeJohnson and Johnson, Raritan, NJ 08869, USA.ORCID 0000-0002-5015-3713
Karen ChiangEVERSANA™, ON L7N 3H8, Canada.ORCID 0000-0003-4972-7537
Xiwu LinJohnson and Johnson, Raritan, NJ 08869, USA.
Winghan Jacqueline KwongJohnson and Johnson, Raritan, NJ 08869, USA.
John MaringwaClinical Pharmacology and Pharmacometrics, Johnson and Johnson, Breda, Netherlands.ORCID 0000-0002-5423-0800
Lingfeng YangJohnson and Johnson, Raritan, NJ 08869, USA.ORCID 0000-0001-8451-7848
Sandhya NairJohnson and Johnson, Beerse, Belgium.
Mahmoud HashimJohnson and Johnson, Beerse, Belgium.
Mi Jun KengJohnson and Johnson, Beerse, Belgium.ORCID 0000-0001-5979-1706
Imtiaz A SamjooEVERSANA™, ON L7N 3H8, Canada.ORCID 0000-0003-1415-8055

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaHumansMaleNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRandomized Controlled Trials as Topicliterature reviewmultiple myelomapopulation-adjusted indirect comparisonsprognostic factorstreatment effect modifiers

Identifiers

PMID40793976
PMCPMC12465902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.